Protein-dependent 'switch' regulates intracellular trafficking in epithelial cells

Dec 11, 2007

With findings highlighted on a recent cover of Developmental Cell, researchers at Weill Cornell Medical College in New York City have shed important new light on key trafficking mechanisms within epithelial cells. Epithelial cells line the outside of nearly all organs.

Specifically, the team has discovered a molecular "switch" in developed epithelial cells that selects from a large family of "motor proteins," called kinesins. Each kinesin facilitates the transport of specific surface markers from production sites inside the cell to their ultimate home on the cell's surface.

"Not only are many more kinesins present in cells than previously thought, but their selectivity helps direct which packages of surface proteins are transported, as well as their ultimate destinations," explains lead researcher Dr. Geri Kreitzer, assistant professor in the department of cell and developmental biology at Weill Cornell Medical College.

"Breakdown in these types of intracellular trafficking pathways is a serious contributing factor to many diseases ranging from cystic fibrosis to cancer," Dr. Kreitzer continues. "So, a better understanding of processes directed by the specific kinesin family members marks a big step forward in developing therapeutics that might someday treat or cure these illnesses. By targeting the individual motors rather than the tracks along which they all move (a current approach used to treat some types of cancer), we could bypass some of the effects on global cellular function that affect patients adversely."

Scientists have long understood the importance of kinesins in the life of the cell, she notes.

"These proteins are essentially 'trains' pulling packets (vesicles) of essential proteins and lipids from production sites in the heart of the cell up to areas on the outer surface, where the cell interacts with its environment," Dr. Kreitzer explains.

These kinesin "trains" work by moving their cargoes along filamentous tracks, known as microtubules. "When everything is working right, appropriate surface markers end up where they need to go. However, in rare cases, mix-ups occur, and they can be devastating -- causing sickness not only of cells but of the organ of which those cells are a part," Dr. Kreitzer explains.

Scientists have spent decades investigating vesicular trafficking. But the exact role for each of the 41 members of the kinesin family has remained unclear.

In their study, Dr. Kreitzer's team focused on four different cell membrane proteins. They knew these proteins were destined to be packed up and transported via microtubules to key spots on the surface of the epithelial cell.

"We knew kinesins played a role in all that -- but did it matter which kinesin?" Dr. Kreitzer says.

To find out, her team inhibited specifically the activity of a series of different kinesins, in turn, then watched to see what happened.

"We discovered something exciting: that the journey a particular surface marker makes depends on a specific member of the kinesin family. What worked for one protein did not work for the others," Dr. Kreitzer says. "That tells us that there's real 'selectivity' going on. It also tells us that the type of kinesin selected is a key piece of information determining where a particular surface protein will go."

"That's great news for drug development, because it means that we might use this selectivity to target the appropriate motor protein whenever a specific pathway goes wrong," Dr. Kreitzer says. "That could potentially mean more effective, targeted therapies with fewer side effects."

The team also discovered that selectivity of the motor for its cargo (passenger) switches after the epithelial cell has differentiated and fully matured. "When we worked with immature, developing cells, the type of kinesin used is clearly different," Dr. Kreitzer points out.

But how does the mature cell decide which kinesin to put to work on a particular transport mechanism"

"Right now, we just don't know," Dr. Kreitzer said. "Figuring out that molecular 'switch' is the next great frontier in this research."

For now, the study's findings hold promise for the study of devastating illnesses caused by defective placement of surface proteins, such as in cystic fibrosis, and even cancer.

"Right now, most chemotherapy targets the whole microtubule 'track' -- that's a really heavy-handed approach that typically affects the cell as a whole and causes serious side effects," notes Dr. Kreitzer.

"Imagine, though, that we could use what we now know about kinesins to target only the specific trafficking machinery that's gone awry," she says. "The result could be better, safer cancer care. And that paradigm holds true for a myriad of other diseases, as well."

Source: New York- Presbyterian Hospital

Explore further: Officials confirm first sighting of rare fox at Yosemite in nearly 100 years

add to favorites email to friend print save as pdf

Related Stories

Super Bowl athletes are scientists at work

34 minutes ago

Seattle Seahawks cornerback Richard Sherman gets called a lot of things. He calls himself the greatest cornerback in the NFL (and Seattle fans tend to agree). Sportswriters and some other players call him ...

Going a long way to do a quick data collection

44 minutes ago

Like many a scientist before me, I have spent this week trying to grow a crystal. I wasn't fussy, it didn't have to be a single crystal – a smush of something would have done – just as long as it had ...

Jay Z to acquire Wimp music service

44 minutes ago

US rap star Jay Z will make a $56-million foray into the music streaming business by taking over the Norwegian service Wimp, its shareholders confirmed Friday.

Recommended for you

Researchers develop new potato cultivar

2 hours ago

Dakota Ruby is the name of a new potato cultivar developed by the NDSU potato breeding project and released by the North Dakota Agricultural Experiment Station. Dakota Ruby has bright red skin, stores well and is intended ...

Researchers develop new soybean variety

2 hours ago

The North Dakota Agricultural Experiment Station has developed and released ND Henson, a conventional soybean variety, according to Rich Horsley, chair of the NDSU Department of Plant Sciences.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.